Drug intelligence / Profile preview

Whittilix

Development stage: Unknown
Lead developer: Ardent Life Sciences
Modality: Small Molecules
Administration: Topical

Overview

**Whittilix** is an Ardent Life Sciences topical fixed-dose dermatology product containing **benzoyl peroxide + salicylic acid**. Benzoyl peroxide provides non-specific antimicrobial activity against acne-associated cutaneous microorganisms and also has keratolytic effects, while salicylic acid promotes desquamation and comedolysis through keratolytic exfoliation. The product is positioned for acne and related skin conditions.

Brand names: Whittilix
Other names: benzoyl peroxide + salicylic acid

Beyond the preview

Go deeper on Whittilix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Whittilix.

Explore the full profile